Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

Core Insights - Revolution Medicines, Inc. announced updated clinical data for elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C non-small cell lung cancer (NSCLC) [1][2] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [9] - The company's R&D pipeline includes RAS(ON) inhibitors designed to suppress various oncogenic variants of RAS proteins, including daraxonrasib, elironrasib, and zoldonrasib [9] Clinical Data Highlights - As of August 4, 2025, elironrasib was administered to 24 heavily pretreated patients with KRAS G12C NSCLC, showing a confirmed objective response rate of 42% and a disease control rate of 79% [2][4] - The median duration of response was 11.2 months, with a median progression-free survival of 6.2 months, and a 12-month overall survival rate of 62% [2][4] Treatment Context - NSCLC accounts for 80%-85% of all lung cancers, with KRAS mutations present in nearly 30% of NSCLC cases, making KRAS G12C the most common variant [5][7] - Elironrasib has received Breakthrough Therapy Designation for treating adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received prior chemotherapy and immunotherapy [4] Upcoming Presentations - The AACR-NCI-EORTC Symposium will feature oral presentations highlighting the clinical activity of elironrasib and encouraging preclinical data supporting the RAS(ON) inhibitor platform [2][6]